Can Receptos' New Drug Beat Biogen?

Receptos shares are surging on positive midstage trial results for a multiple sclerosis treatment. Could Receptos challenge Teva and Biogen Idec in the indication one day?

Jun 10, 2014 at 2:30PM

Receptos (NASDAQ:RCPT) shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis.

The midstage trial results offer investors hope that Receptos' product will eventually make its way to market and challenge market share leaders Biogen Idec (NASDAQ:BIIB). and Teva Pharmaceutical (NYSE:TEVA)

RCPT Chart

RCPT data by YCharts.

First, a bit of background
In multiple sclerosis, the protective shield surrounding nerves is damaged by the body's immune system. That damage results in a miscommunication in the body's central nervous system, leading to slate of potentially debilitating symptoms including muscle weakness, loss of balance, and tremors. 

It's estimated that more than 2 million people globally suffer from multiple sclerosis, including 1.1 million in the U.S. and Europe.

Since there isn't a cure for multiple sclerosis, treatment is focused on reducing the number of annual relapses in an effort to delay disease progression and nerve damage. Those treatments include a range of injectable drugs and a new class of oral pharmaceuticals that combined produce billions of dollars in annual sales.

Teva's Copaxone is one of the most widely prescribed of these treatments. In 2012, Copaxone's market share of MS scripts stood at 40%; however, the introduction of new treatments reduced the drug's market share to roughly 35% last year, and estimates suggest Copaxone's share will drop to 25% in 2014. Nonetheless, the drug still generated more than $1 billion in sales for Teva in the first quarter.

Biogen has been a dominant player in MS for years thanks to its injectable drugs Avonex and Tysabri, which combined to produce $1.2 billion in sales during the first quarter.

Meanwhile, Biogen's rising star Tecfidera won FDA approval in March 2013 and has already become the most widely used oral MS treatment in America, displacing Novartis' oral MS drug Gilenya, which had sales of $1.9 billion in 2013.

Sales of Tecfidera reached $500 million in the first quarter. That $2 billion annualized run rate is likely to head even higher this year as Tecfidera is now launching abroad. Biogen's drug is a big reason for Copaxone's market share decline.

Advancing a new therapy
The sheer size of the MS patient population and multiple blockbuster drugs have caught the attention of biotech companies such as Receptos that are eager to tap into this lucrative market.

Receptos' MS drug RPC1063 targets the S1P1R pathway, altering the migration pattern of S1P1R-expressed white blood cells so that they avoid areas of inflammation. Given that previous research suggests that S1P1R overexpression is found in both nonactive and active MS, RPC1063's ability to control S1P1R activity may succeed in reducing the number of MS relapses annually.

The company's phase 2 study wasn't designed to measure annualized relapse rates (that will be studied in phase 3), but rather to determine whether RPC1063 reduced the total number of MS lesions between the 12th and 24th week of treatment. The drug succeeded in reducing the number of lesions by 86%. The safety profile indicated that RPC1063 seemed to have a similar adverse event profile to placebo. 

If that holds up in late-stage studies, RPC1063 could have an advantage over competing drugs, many of which come with cardiovascular risk or danger to the liver.

Fool-worthy final thoughts
Receptos' phase 2 trial only involved 258 patients; the phase 3 trial, which kicked off in December, plans to enroll 1,300 patients. Whether the drug succeeds in reducing annual relapses and its safety profile holds up in the far larger patient population remains to be seen. Plenty of drugs perform well in midstage trials, yet fail in phase 3.

However, since the phase 3 trial pits RPC1063 head-to-head against Biogen's Avonex, a win could create a blockbuster. Fools should remember that RPC1063 is Receptos' lead drug, making it a speculative investment best suited only for aggressive investors.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers